Jazz Pharmaceuticals Q2 revenue rises 16% to $1.2 billion; raises 2026 guidance
Jazz Pharmaceuticals reported second quarter 2026 total revenues of $1.2 billion, up 16% from a year earlier, and raised its full-year 2026 revenue guidance to $4.60 billion-$4.75 billion from $4.25 billion-$4.50 billion. GAAP diluted earnings were $2.78 per share, compared with a loss of $11.74 per share in the year-earlier quarter, which included a $905.4 million acquired in-process R&D charge. For shareholders, the filing shows higher revenue, a higher revenue outlook and a return to profit on a GAAP basis.
Key points
- 2Q26 total revenues were $1,208.3 million, up from $1,045.7 million in 2Q25; Xywav net product sales rose 13% to $471.2 million.
- 2026 total revenue guidance was raised to $4,600 million-$4,750 million, from $4,250 million-$4,500 million given May 5, 2026.
- 2Q26 GAAP diluted EPS was $2.78 and non-GAAP adjusted EPS was $5.71; 2Q26 included $77.0 million of acquired IPR&D expense tied to AbCellera and Werewolf.
- Cash, cash equivalents and investments were $2.2 billion at June 30, 2026, after repaying $1.0 billion of 2.00% exchangeable senior notes in June 2026.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.